Sponsor
Honor's Department
Advisor(s)
Susan Bates, PhD
Ohio Northern University
Chemistry & Biochemistry, Science, Technology, and Mathematics
s-bates@onu.edu
Document Type
Poster
Location
ONU McIntosh Center; Activities Room
Start Date
22-4-2022 10:00 AM
End Date
22-4-2022 11:00 AM
Abstract
Alzheimer’s Disease (AD) affects over 5.8 million people in the United States each year. This number keeps growing and there’s no model predicting a decrease in frequency any time soon. AD is an age dependent disease, with an increase in symptoms and hallmarks as the patient ages. Hallmarks of AD include: neurofibrillary tangles, senile plaques, neuronal death, cortical shrinkage, enlarged ventricles, and shrinking hippocampus. These occur due to the failing of the proteostasis network, or the entropically bound network of proteins whose main goal is to keep the proteins in the lowest energy state which is typically the correctly folded state. Current AD diagnostic tools include biomarker tests such as testing of the cerebrospinal fluid for protein concentrations, magnetic resonance imaging (MRI), and positron emission tomography (PET). Yates et al. are developing a new technique that will be able to detect that conformation and quantity of proteins in a single cell type. Covalent Protein Painting (CPP) uses specific isotope labeling of solvent accessible lysine resides along with mass spectrometry to gain insight into the protein’s folding and misfolding patterns. Currently, there is a monoclonal antibody treatment in clinical trials for AD which dissociates the plaques in the brain.
Recommended Citation
Gouge, Melissa, "Alzheimer’s Disease: Current Treatments and New Studies- An Honors Capstone Enhancement" (2022). ONU Student Research Colloquium. 3.
https://digitalcommons.onu.edu/student_research_colloquium/2022/posters/3
Open Access
Available to all.
Alzheimer’s Disease: Current Treatments and New Studies- An Honors Capstone Enhancement
ONU McIntosh Center; Activities Room
Alzheimer’s Disease (AD) affects over 5.8 million people in the United States each year. This number keeps growing and there’s no model predicting a decrease in frequency any time soon. AD is an age dependent disease, with an increase in symptoms and hallmarks as the patient ages. Hallmarks of AD include: neurofibrillary tangles, senile plaques, neuronal death, cortical shrinkage, enlarged ventricles, and shrinking hippocampus. These occur due to the failing of the proteostasis network, or the entropically bound network of proteins whose main goal is to keep the proteins in the lowest energy state which is typically the correctly folded state. Current AD diagnostic tools include biomarker tests such as testing of the cerebrospinal fluid for protein concentrations, magnetic resonance imaging (MRI), and positron emission tomography (PET). Yates et al. are developing a new technique that will be able to detect that conformation and quantity of proteins in a single cell type. Covalent Protein Painting (CPP) uses specific isotope labeling of solvent accessible lysine resides along with mass spectrometry to gain insight into the protein’s folding and misfolding patterns. Currently, there is a monoclonal antibody treatment in clinical trials for AD which dissociates the plaques in the brain.
Notes
This presentation is part of the Honors Capstone Enhancement Presentation series.